DnB Asset Management’s Krystal Biotech KRYS Stock Holding History

DnB Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$450K	Sell	1,211 -1,889	-61%	-$564K	﹤0.01%	843
2026 Q1	$801K	Buy	3,100 +7	+0.2%	+$1.86K	﹤0.01%	667
2025 Q4	$763K	Buy	3,093 +737	+31%	+$155K	﹤0.01%	656
2025 Q3	$416K	Buy	2,356 +625	+36%	+$93.5K	﹤0.01%	678
2025 Q2	$238K	Sell	1,731 -48	-3%	-$7.05K	﹤0.01%	687
2025 Q1	$321K	Buy	1,779 +242	+16%	+$40.7K	﹤0.01%	685
2024 Q4	$241K	Sell	1,537 -759	-33%	-$135K	﹤0.01%	706
2024 Q3	$418K	Sell	2,296 -57	-2%	-$11K	﹤0.01%	665
2024 Q2	$432K	Buy	2,353 +53	+2%	+$8.9K	﹤0.01%	660
2024 Q1	$409K	Buy	+2,300	New	+$319K	﹤0.01%	666
2022 Q2	–	Sell	-24,500	Closed	-$1.63M	–	661
2022 Q1	$1.63M	Sell	24,500 -11,140	-31%	-$695K	0.01%	571
2021 Q4	$2.49M	Buy	+35,640	New	+$2.07M	0.01%	521

Other funds holding KRYS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

DnB Asset Management's KRYS Position: Q2 2026 in Review

DnB Asset Management reduced its Krystal Biotech (KRYS) stake by 61% in Q2 2026, selling an estimated $564K and leaving 1,211 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #843.

DnB Asset Management first reported a position in KRYS in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.49M in Q4 2021. 272 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

DnB Asset Management held 1,211 shares of Krystal Biotech worth $450K as of Q2 2026.
DnB Asset Management sold 1,889 Krystal Biotech shares in Q2 2026, an estimated $564K.
Krystal Biotech made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #843 holding.
DnB Asset Management first reported a position in Krystal Biotech in Q4 2021 and has held it in 12 quarters since.
DnB Asset Management's Krystal Biotech position peaked at $2.49M in Q4 2021.
272 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.